Xeomin vs Jeuveau: Differences, Cost & Which Is Right for You (2026)

Xeomin (incobotulinumtoxinA) and Jeuveau (prabotulinumtoxinA-xvfs) are two of the most common Botox alternatives. Both are botulinum toxin type A neuromodulators that relax the muscles causing frown lines, and in skilled hands their cosmetic results are very close. The meaningful differences are in formulation, onset speed, FDA-approved uses, and how each is priced.

FDA status: Both are FDA-approved for moderate to severe glabellar (frown) lines between the eyebrows. Xeomin is also FDA-approved for several medical conditions; Jeuveau is approved for cosmetic frown lines only. Treating the forehead, crow's feet, or other facial areas with either product is common but off-label. Unit counts are not interchangeable across brands. This is educational content, not medical advice.

Xeomin vs Jeuveau at a glance

Xeomin and Jeuveau are close cousins: both are purified botulinum toxin type A, both are injected into the same small facial muscles, and both deliver comparable frown-line smoothing that lasts roughly three to four months. Where they part ways is in what is actually in the vial, how quickly you see a result, and what each is legally approved to treat. The table below summarizes the practical head-to-head.

Neither product is objectively better. For most people the choice comes down to your injector's experience, the area being treated, and price on the day. The brand matters far less than the hands holding the syringe.

What Xeomin and Jeuveau have in common

Both Xeomin and Jeuveau are botulinum toxin type A, the same broad family as Botox and Dysport. They work identically: injected into a muscle, the toxin blocks the release of acetylcholine, the chemical signal that tells the muscle to contract. The muscle relaxes, and the overlying skin stops creasing, softening dynamic wrinkles such as the vertical frown lines (11s) between the brows.

The practical similarities run deep. Both are dosed on a roughly 1:1 unit scale with Botox, so a treatment plan that uses, say, 20 units of Botox will use a comparable number of Xeomin or Jeuveau units. Both take full effect within about one to two weeks and last approximately three to four months before muscle activity gradually returns. Both are prescription-only and must be reconstituted and injected by a trained, licensed medical professional. Both carry the same class-wide FDA boxed warning about the toxin potentially spreading from the injection site, a rare event at cosmetic doses. And clinical experience shows their aesthetic outcomes for frown lines are broadly interchangeable, which is why many injectors stock more than one and choose per patient.

Key differences between Xeomin and Jeuveau

Formulation is the headline difference. Xeomin is manufactured to remove the accessory (complexing) proteins that surround the active toxin, leaving only the pure neurotoxin. This is why it is marketed as "naked" Botox and why it does not require refrigeration before reconstitution. The theoretical benefit is a lower chance of the immune system forming neutralizing antibodies over years of repeat treatment, which could otherwise reduce a product's effectiveness. Evidence for this mattering in typical cosmetic use is limited, but it can be relevant for people who need frequent, high-dose therapeutic injections. Jeuveau retains complexing proteins, similar to Botox.

Onset differs slightly. Many patients and injectors report Jeuveau kicks in a touch faster, often noticeable in about two to three days, while Xeomin tends to appear around three to four days. Both reach full effect within one to two weeks, so the head start is modest.

FDA approvals differ most in scope. Xeomin, approved in the US in 2010, carries multiple therapeutic indications alongside its cosmetic frown-line approval, including cervical dystonia, blepharospasm, upper-limb spasticity, and chronic drooling. Jeuveau hit the US market in February 2019 and is approved for one thing only: the cosmetic improvement of frown lines. It has no medical indications, which is why it is sometimes called a purely aesthetic "Newtox." A common question is why Jeuveau was "banned." In 2020 a US trade court ordered a temporary import restriction stemming from a trade-secret dispute between Evolus and rivals Allergan and Medytox over manufacturing methods. That was a business and patent matter, later settled in 2021, not an FDA safety action, and Jeuveau remained available in the US.

Which may be better for you

There is no universally superior product, but a few tendencies can guide the conversation with your injector. Xeomin may appeal if you have been getting neurotoxin for years and want the protein-free formula, if you have previously experienced reduced response to another toxin (possible antibody resistance), or if you value that the same product is also used for medical indications. Some people simply prefer its clean formulation on principle.

Jeuveau may suit you if a slightly faster onset matters (for example, an event in a few days), if your clinic prices it competitively, or if you are a healthy adult specifically seeking frown-line treatment, which is exactly what it was designed and approved to do. On the frequently asked question of whether Xeomin looks more natural: in skilled hands, neither product inherently produces a more natural result. Natural-looking outcomes come from conservative, well-placed dosing and an injector who preserves some movement, not from the brand in the vial. Both can look soft and undone or frozen and heavy depending entirely on technique and dose. If you are new to injectables, choose the injector first, discuss your goals, and let them recommend the product they use most confidently for your anatomy.

Safety and side effects of both

Xeomin and Jeuveau have very similar, well-characterized safety profiles, comparable to Botox and Dysport. The most common side effects are mild and temporary: redness, swelling, or bruising at the injection site, a short-lived headache, and, less often, temporary eyelid or brow droop if the toxin affects a nearby muscle. These effects resolve as the product wears off. On the common question of how safe Jeuveau is, and whether Jeuveau is safer than Botox: all four botulinum toxin type A products carry the same FDA class labeling and, at cosmetic doses, have strong safety records when administered by trained clinicians. No cosmetic neurotoxin is meaningfully "safer" than another; risk is driven far more by injector skill, dose, and product handling than by brand.

All botulinum toxins carry an FDA boxed warning noting that, rarely, the toxin can spread beyond the injection site and cause symptoms such as muscle weakness, trouble swallowing, or breathing difficulty. This is exceedingly rare at the small doses used cosmetically but is why these are prescription products given only by qualified professionals. Neither product should be used during pregnancy or breastfeeding, in people with certain neuromuscular disorders, or where there is an active infection at the injection site. Always disclose your full medical history and current medications, since some can increase bruising or interact with neurotoxins.

Cost comparison: Xeomin vs Jeuveau

Because Xeomin and Jeuveau are both dosed roughly 1:1 with Botox, cost is usually compared per unit, and their per-unit prices tend to land in a similar range that is often modestly below Botox. Prices vary widely by region, provider experience, and clinic, so treat any figure as a ballpark, not a quote. As a rough guide, per-unit pricing commonly falls somewhere in the low tens of dollars, meaning a frown-line treatment of about 20 units often totals in the low-to-mid few-hundred-dollar range. Many practices also run membership pricing or manufacturer rewards (Evolus and Merz both offer loyalty programs) that shift the real cost.

A frequent question is how many units of Xeomin people typically get. For the frown lines, plans commonly use around 20 units, similar to Botox; treating the forehead and crow's feet as well can push a full upper-face session higher, and men often need more units than women because of stronger muscles. Another common question is why Dysport can look more expensive or cheaper than Xeomin. The trap is comparing per-unit prices across brands: Dysport uses a different, smaller unit scale (it takes roughly two to three Dysport units to equal one Xeomin or Botox unit), so its lower per-unit price does not mean a lower total. Compare total treatment cost for your specific areas, not sticker price per unit. Neurotoxin results are temporary, so budget for maintenance every three to four months rather than a one-time cost.

How to choose and find a provider

The single most important decision is not Xeomin versus Jeuveau; it is who injects you. Both products are excellent tools, and an experienced, licensed injector using either will outperform a novice using your preferred brand. Look for a board-certified dermatologist, plastic surgeon, or a licensed nurse injector or physician assistant working under appropriate medical supervision, ideally someone who treats the area you care about frequently and can show before-and-after results.

At your consultation, ask which product they recommend for your anatomy and why, how many units they anticipate, the all-in price, and what to expect for onset and follow-up. A good injector will happily explain trade-offs, may suggest a two-week touch-up, and will dose conservatively for a natural result rather than promising a frozen look. If you have had a weaker-than-expected response to a toxin before, mention it, since that may steer the choice toward Xeomin. When you are ready, use the provider hand-off below to find a qualified injector near you who offers these treatments, then book a consultation to confirm the right product and plan for your goals.